AGIO Quote, Financials, Valuation and Earnings

Haemonetics has a net margin of -1115.71% compared to Agios Pharmaceuticals's net margin of 9.79%. Agios Pharmaceuticals's return on equity of 71.3% beat Haemonetics's return on equity of 13.51%.

Agios Pharmaceuticals has a consensus price target of $57.00, signalling upside risk potential of 71.07%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 38.57%. Given that Agios Pharmaceuticals has higher upside potential than Haemonetics, analysts believe Agios Pharmaceuticals is more attractive than Haemonetics.

Agios Pharmaceuticals has a beta of 0.874, which suggesting that the stock is 12.615% less volatile than S&P 500. In comparison Haemonetics has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.02%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $9M, which are smaller than Haemonetics quarterly revenues of $345.5M. Agios Pharmaceuticals's net income of $947.9M is higher than Haemonetics's net income of $33.8M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 2.93x while Haemonetics's PE ratio is 33.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 57.66x versus 3.02x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -1115.71% compared to Agios Pharmaceuticals's net margin of -49.65%. Agios Pharmaceuticals's return on equity of 71.3% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Agios Pharmaceuticals has a consensus price target of $57.00, signalling upside risk potential of 71.07%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 423.91%. Given that NovaBay Pharmaceuticals has higher upside potential than Agios Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Agios Pharmaceuticals.

Agios Pharmaceuticals has a beta of 0.874, which suggesting that the stock is 12.615% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $9M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Agios Pharmaceuticals's net income of $947.9M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 2.93x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 57.66x versus 0.08x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -1115.71% compared to Agios Pharmaceuticals's net margin of 25.43%. Agios Pharmaceuticals's return on equity of 71.3% beat ResMed's return on equity of 23.76%.

Agios Pharmaceuticals has a consensus price target of $57.00, signalling upside risk potential of 71.07%. On the other hand ResMed has an analysts' consensus of $256.02 which suggests that it could grow by 11.88%. Given that Agios Pharmaceuticals has higher upside potential than ResMed, analysts believe Agios Pharmaceuticals is more attractive than ResMed.

Agios Pharmaceuticals has a beta of 0.874, which suggesting that the stock is 12.615% less volatile than S&P 500. In comparison ResMed has a beta of 0.698, suggesting its less volatile than the S&P 500 by 30.155%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.88% to investors and pays a quarterly dividend of $0.53 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Agios Pharmaceuticals quarterly revenues are $9M, which are smaller than ResMed quarterly revenues of $1.2B. Agios Pharmaceuticals's net income of $947.9M is higher than ResMed's net income of $311.4M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 2.93x while ResMed's PE ratio is 30.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 57.66x versus 7.02x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Twist Bioscience has a net margin of -1115.71% compared to Agios Pharmaceuticals's net margin of -40.91%. Agios Pharmaceuticals's return on equity of 71.3% beat Twist Bioscience's return on equity of -38.12%.

Agios Pharmaceuticals has a consensus price target of $57.00, signalling upside risk potential of 71.07%. On the other hand Twist Bioscience has an analysts' consensus of $52.14 which suggests that it could grow by 21.96%. Given that Agios Pharmaceuticals has higher upside potential than Twist Bioscience, analysts believe Agios Pharmaceuticals is more attractive than Twist Bioscience.

Agios Pharmaceuticals has a beta of 0.874, which suggesting that the stock is 12.615% less volatile than S&P 500. In comparison Twist Bioscience has a beta of 1.846, suggesting its more volatile than the S&P 500 by 84.618%.

Agios Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Agios Pharmaceuticals pays -- of its earnings as a dividend. Twist Bioscience pays out -- of its earnings as a dividend.

Agios Pharmaceuticals quarterly revenues are $9M, which are smaller than Twist Bioscience quarterly revenues of $84.7M. Agios Pharmaceuticals's net income of $947.9M is higher than Twist Bioscience's net income of -$34.7M. Notably, Agios Pharmaceuticals's price-to-earnings ratio is 2.93x while Twist Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Agios Pharmaceuticals is 57.66x versus 7.92x for Twist Bioscience. Usually stocks with elevated PS ratios are considered overvalued.